[1] Davies L, Welch HG.Current thyroid cancer trends in the United States[J]. JAMA Otolaryngol Had Neck Surg, 2014, 140(4): 317-322.
[2] Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cance [J]. BMJ, 2014, 348: g3045.
[3] Nix P,Nicolaides A, Coatesworth AP. Thyroid cancer review1: presentation and investigation of thyroid cancer[J]. Int J Clin Pract, 2005, 59(11):1340-1344.
[4] Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay [J]. Cancer, 2014, 120(23): 3627-3634.
[5] Lalami Y, Awada A. Recurrent thyroid cancer: a molecular-based therapeutic break -through [J]. Curr Opin Oncol, 2011,23(3): 235-240.
[6] Gao M, Zheng XQ. Thyroid cancer over the past decade and the next decade [J]. Chinese Journal of Clinical Oncology, 2018, 45(1): 2-6. (in Chinese)
高明, 郑向前. 甲状腺癌过去与未来十年 [J]. 中国肿瘤临床, 2018,45(1):2-6.
[7] Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy[J]. Lancet, 2005,365(9458): 488-492.
[8] Guarino V, Faviana P, Salvatore G,et al. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness [J]. J Clin Endocrinol MeTab, 2005,90(9): 5270-5278.
[9] Guba?a E, Wiench M, Oczko-Wojciechowska M,et al. Gene expression analysis by DNA microarray in papillary thyroid cancer. Endokrynol Pol [J]. Endokrynol Pol, 2005, 56(5):752-727.
[10]Hawthorn L, Stein L, Varma R, et al. TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma [J]. Head Neck, 2004, 26(12): 1069-1083.
[11]Lamba Saini M,Bouzin C,Weynand B, et al. An appraisal of proliferation and apoptotic markers in papillary thyroid carcinoma: an automated analysis [J]. PLoS One, 2016, 11(2): e0148656.
[12]da Silveira Mitteldorf CA, Juliana Moreira, de Sousa-Canavez, et al.FN1, GALE, MET, and QPCT overexpression in papillary thyroid carcinoma: molecular analysis using frozen tissue and routine fine-needle aspiration biopsy samples [J]. Diagn Cytopathol, 2011, 39(8): 556-561.
[13]Koo BS, Kim JM, Seo ST, et al.Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma [J]. Ann Surg Oncol, 2014,21(7):2310-2317.
[14]Zhang KE, Ge SJ, Lin XY, et al. Intercellular adhesion molecule 1 is a sensitive and diagnostically useful immunohistochemical marker of papillary thyroid cancer (PTC) and of PTC-like nuclear alterations in Hashimoto's thyroiditis [J]. Oncol Lett, 2016, 11(3): 1722-1730.
[15]Buergy D, Weber T, Maurer GD, et al. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies [J]. Int J Cancer, 2009, 125(4): 894-901.
[16]Qiu J, Zhang W, Xia Q, et al. Investigating the mechanisms of papillary thyroid carcinoma using transcriptome analysis [J]. Mol Med Rep, 2017, 16(5): 5954-5964.
[17]Ito Y,Takano T, Miyauchi A. Apolipoprotein e expression in anaplastic thyroid carcinoma [J]. Oncology, 2006,71(5-6): 388-393.
[18]Chitikova Z, Pusztaszeri M, Makhlouf AM. Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis [J]. Oncotarget, 2015, 6(13): 10978-10993.
[19]Zhang S, Wang Y, Chen M, et al. CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma [J]. Sci Rep, 2017,7:44033.
[20]Law NC, White MF, Hunzicker-Dunn ME. G protein-coupled receptors (GPCRs) that signal via protein kinase A (PKA) cross-talk at insulin receptor substrate 1 (IRS1) to activate the phosphatidylinositol 3-kinase (PI3K)/AKT pathway [J]. J Biol Chem, 2016, 291(53): 27160-27169.
[21]Takeda M, Mikami T, Numata Y,et al. Yoshiko numata papillary thyroid carcinoma with heterotopic ossification is a special subtype with extensive progression[J]. Am J Clin Pathol, 2013, 139(5): 587-598.
[22]Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. [J]. Curr Opin Cell Biol, 1998,10(2): 205-219.
[23]Luo A, Yu X, Li G. Differentiation-associated genes regulated by c-jun and decreased in the progression of esophageal squamous cell carcinoma [J]. PLoS One, 2014, 9(5): e96610.
|